ODT Odonate Therapeutics Inc.

28.98
-0.07  -0%
Previous Close 29.05
Open 29.25
Price To Book 5
Market Cap 929,794,059
Shares 32,083,991
Volume 59,174
Short Ratio
Av. Daily Volume 105,440
Stock charts supplied by TradingView

NewsSee all news

  1. Odonate Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2019

    Odonate Therapeutics, Inc. (NASDAQ:ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results

  2. Odonate Therapeutics Announces Completion of Enrollment in CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast Cancer

    Odonate Therapeutics, Inc. (NASDAQ:ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the completion of

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 top-line data due 3Q 2020.
Tesetaxel - CONTESSA
Metastatic breast cancer (MBC)
Phase 2 trial initiation announced March 4, 2019.
Tesetaxel - Contessa 2
Metastatic breast cancer (MBC)

Latest News

  1. Odonate Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2019

    Odonate Therapeutics, Inc. (NASDAQ:ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results

  2. Odonate Therapeutics Announces Completion of Enrollment in CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast Cancer

    Odonate Therapeutics, Inc. (NASDAQ:ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the completion of